About: CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients
Creator	Zhang, Wei Li, Xi Hu, Cheng-Ping Liu, Zhao-Qian Qiu, Cheng-Feng Tan, Li-Ming Yin, Ji-Ye Zhou, Hong-Hao Zhu, Tao
Source	Medline; PMC
abstract	Cisplatin-based chemotherapy is the foundation of treatment for major non-small cell lung cancer (NSCLC) patients. However, cisplatin resistance is still a challenging issue, and the molecular mechanisms underlying this resistance remain to be fully explored. CLEC4M, a Ca(2+)-dependent C-type lectin, has recently been found to correlate with tumourigenesis. This study mainly focused on whether CLEC4M impacts clinical prognosis and how CLEC4M contributes to cisplatin resistance in NSCLC. Our results found that CLEC4M was correlated with poor prognosis in patients with lung cancer. In addition, a positive association between CLEC4M expression and the IC50 values of cisplatin was found, which suggests that CLEC4M may impact cisplatin sensitivity. In vitro results from cultured A549 and H1299 cells confirmed that CLEC4M could enhance cisplatin resistance, while CLEC4M knockdown led to higher sensitivity to cisplatin in these cells. Further experiments showed that the underlying mechanisms included inhibition of cisplatin-induced cell apoptosis by CLEC4M and improved DNA repair capacity by upregulating XPA and ERCC1 expression. In addition, CLEC4M was able to promote cell migration with or without cisplatin treatment. Collectively, these findings suggest the potential clinical significance of CLEC4M inhibition in overcoming cisplatin resistance in NSCLC patients.
has issue date	2019-10-19(xsd:dateTime)
bibo:doi	10.7150/jca.30139
bibo:pmid	31772670
has license	cc-by
sha1sum (hex)	3e9d0220802e3e3fba0b25f1e2cd46b9412c4317
schema:url	https://doi.org/10.7150/jca.30139
resource representing a document's title	CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients
has PubMed Central identifier	PMC6856750
has PubMed identifier	31772670
schema:publication	J Cancer
resource representing a document's body	covid:3e9d0220802e3e3fba0b25f1e2cd46b9412c4317#body_text
is schema:about of	named entity 'LUNG CANCER' named entity 'CELLS' named entity 'INHIBITION' named entity 'POSITIVE' named entity 'INCLUDED' named entity 'RESISTANCE' named entity 'ERCC1' named entity 'MAJOR' named entity 'EXPRESSION' named entity 'ISSUE' named entity 'POTENTIAL' named entity 'INDUCED' named entity 'H1299' named entity 'STUDY' named entity 'CHEMOTHERAPY' named entity 'NSCLC' named entity 'apoptosis' named entity 'prognosis' named entity 'NON-SMALL CELL LUNG CANCER' named entity 'FINDINGS' named entity 'UNDERLYING' named entity 'OUR' named entity 'ASSOCIATION' named entity 'A549' named entity 'MECHANISMS' named entity 'DNA REPAIR CAPACITY' named entity 'FOCUSED' named entity 'RECENTLY' named entity 'CULTURED' named entity 'FULLY' named entity 'PROMOTE' named entity 'HIGHER' named entity 'RESULTS' named entity 'IC50' named entity 'ENHANCE' named entity 'CLINICAL' named entity 'BASED' named entity 'THESE' named entity 'CISPLATIN RESISTANCE' named entity 'LED' named entity 'XPA' named entity 'CISPLATIN' named entity 'EXPERIMENTS' named entity 'PROGNOSIS' named entity 'DEPENDENT' named entity 'POOR PROGNOSIS' named entity 'HOW' named entity 'IMPROVED' named entity 'CLINICAL SIGNIFICANCE' named entity 'SENSITIVITY' named entity 'TYPE' named entity 'FOUND' named entity 'SUGGEST' named entity 'APOPTOSIS' named entity 'ADDITION' named entity 'TUMOURIGENESIS' named entity 'VALUES' named entity 'CELL MIGRATION' named entity 'IN VITRO' named entity 'LECTIN' named entity 'CONFIRMED' named entity 'FOUNDATION' named entity 'IMPACT' named entity 'CELL' named entity 'CORRELATED' named entity 'PATIENTS' named entity 'TREATMENT' named entity 'CLEC4M' named entity 'IMPACTS' named entity 'MOLECULAR' covid:arg/3e9d0220802e3e3fba0b25f1e2cd46b9412c4317 named entity 'cisplatin' named entity 'focused'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software